SQZ Biotechnologies Company
Cell Squeeze® technology platform for non-viral delivery of transcription factors into cells to generate therapeutic cell replacements
- Sector
- Biotech
- Headquarters
- Somerville, MA
- Founded
- 2013
- Latest Form D
- $66.3M, Jun 2020
- Total capital
- $161M
- Federal grants
- $2.7M
- 4 awards · 2015–2022
- Rank in peer group#27 of 36
- Private capital raised
- $158M
- 5 Form D · last Jun 2020
- 77 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 37 pending · first 2023
- Rank in peer group#7 of 36
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Microfluidic cell squeezing platform for the transdifferentiation of somatic cells for efficient generation of a cell replacement therapy for Parkinsons Disease$1M
- Private capital raisedForm D · SEC · 5th filing$66.3M
- Private capital raisedForm D · SEC · 4th filing$71.3M
- Federal grantHealth and Human S · Phase I · Cell Engineering Platform for Red Blood Cell Mediated Treatment of Autoimmune Diseases$250K
- Private capital raisedForm D · SEC · 3rd filing$15.7M
- Federal grantNSF · Phase II · SBIR Phase II: Development of an Intracellular Delivery Platform for Accelerated Drug Discovery Using Genetically Engineered Human Immune Cells$1.2M
- Private capital raisedForm D · SEC · 2nd filing$5M
- Private capital raisedForm D · SEC · 1st filing$15K
Show 1 earlier federal award
- Federal grantNSF · Phase I · SBIR Phase I: An Automated Microfluidic Platform for Delivery of Biomolecules Into Cells$150K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 36 peers
Line = medianBiotech · Platform
- Federal grantsBelow median
- Granted patents#7 · top 19%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Agustin Lopez-MarquezExecutive OfficerNamed in SEC Form D filings
- Alexandra W. BalcomExecutive OfficerNamed in SEC Form D filings
- Alex A. BalcomExecutive OfficerNamed in SEC Form D filings
- Amy W. SchulmanExecutive Officer, DirectorNamed in SEC Form D filings
- Armon ShareiExecutive Officer, DirectorNamed in SEC Form D filings
- Armon Sharei, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
Show all 25 people
- David W. FirstExecutive OfficerNamed in SEC Form D filings
- Eric W. MoessingerDirectorNamed in SEC Form D filings
- Garry A. NicholsonDirectorNamed in SEC Form D filings
- Howard A. BernsteinExecutive OfficerNamed in SEC Form D filings
- Howard W. Bernstein, M.D., Ph.D.Executive OfficerNamed in SEC Form D filings
- Jonathan FlemingDirectorNamed in SEC Form D filings
- Klavs JensenExecutive Officer, DirectorNamed in SEC Form D filings
- Klavs F. Jensen, Ph.D.DirectorNamed in SEC Form D filings
- Kris A. ElverumExecutive OfficerNamed in SEC Form D filings
- Lawrence W. KnopfExecutive OfficerNamed in SEC Form D filings
- Marc W. EliaDirectorNamed in SEC Form D filings
- Mark W. Murcko, Ph.D.DirectorNamed in SEC Form D filings
- Oliver W. Rosen, M.D.Executive OfficerNamed in SEC Form D filings
- Pushkal W. GargDirectorNamed in SEC Form D filings
- Robert LangerDirectorNamed in SEC Form D filings
- Robert Langer, Ph.D.DirectorNamed in SEC Form D filings
- Robert Langer, Sc.D.DirectorNamed in SEC Form D filings
- Teri W. LoxamExecutive OfficerNamed in SEC Form D filings
- Zafrira W. AvnurDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 40- GrantedDELIVERY OF BIOMOLECULES TO PBMCs TO MODIFY AN IMMUNE RESPONSEUSPTOUS 11,692,168
- GrantedCartridge For Use In A System For Delivery Of A Payload Into A CellUSPTOUS 11,679,388
- GrantedIntracellular Delivery Of Biomolecules To Cells Comprising A Cell WallUSPTOUS 11,613,759
Show all 40 patent records
- DELIVERY OF BIOMOLECULES TO PBMCs TO MODIFY AN IMMUNE RESPONSEJul 4, 2023 · US 11,692,168Granted
- Cartridge For Use In A System For Delivery Of A Payload Into A CellJun 20, 2023 · US 11,679,388Granted
- Intracellular Delivery Of Biomolecules To Cells Comprising A Cell WallMar 28, 2023 · US 11,613,759Granted
- Intracellular Delivery Of Biomolecules To Modulate Antibody ProductionOct 14, 2021 · Application 16769993Pending
- Intracellular Delivery Of Biomolecules Mediated By A Surface With PoresDec 19, 2019 · Application 15757312Pending
- Intracellular Delivery Of ComplexesJan 17, 2019 · Application 16068631Pending
- Methods To Generate Enhanced Tumor Infiltrating Lymphocytes Through Microfluidic DeliveryApplication PCTUS2022074273Pending
- Enhanced Antigen Presenting Cell FormulationsApplication 63369715Pending
- Modified Hematopoietic Stem Cells And Uses ThereofApplication PCTUS2023060116Pending
- Reprogramming Of Cells With Self-amplifying RnaApplication 63345339Pending
- Methods For Delivering Genome Editing Molecules To The Nucleus Or Cytosol Of A Cell And Uses ThereofApplication PCTUS2022028546Pending
- Reprogramming Of Cells And Uses ThereofApplication PCTUS2022023356Pending
- Methods Of Producing Glial Cells And Uses ThereofApplication 63313094Pending
- Modified Hematopoietic Stem Cells And Uses ThereofApplication 63296544Pending
- Cartridges And Devices For Use In A System For Delivery Of A Payload Into A CellApplication 63346634Pending
- Modified Hematopoietic Stem Cells And Uses ThereofApplication 63374622Pending
- Methods For Treating Cancers With Modified PbmcsApplication PCTUS2021065362Pending
- FORMULATIONS OF PBMCsApplication PCTUS2021065352Pending
- High-throughput Microfluidic Chip Having Parallelized Constrictions For Perturbing Cell MembranesApplication PCTUS2021073119Pending
- Microfluidic Chip Having Increased Throughput For Use In A System For Delivery Of A Payload Into A CellApplication PCTUS2021073121Pending
- METHODS FOR TREATING CANCERS WITH MODIFIED PBMCsApplication 63278788Pending
- METHODS FOR TREATING CANCERS WITH MODIFIED PBMCsApplication 63249739Pending
- Reprogramming Of Cells And Uses ThereofApplication 63240739Pending
- Methods To Stimulate Hla-agnostic Immune Responses To Proteins Using Nucleated CellsApplication PCTUS2021048771Pending
- Methods To Generate Enhanced Tumor Infiltrating Lymphocytes Through Microfluidic DeliveryApplication 63227253Pending
- Methods To Stimulate Immune Responses To Mutant Ras Using Nucleated CellsApplication PCTUS2021043567Pending
- Methods To Stimulate Immune Responses To Mutant Ras Using Anucleate CellsApplication PCTUS2021043568Pending
- Point Of Care System For Automatically Processing CellsApplication PCTUS2021033764Pending
- METHODS FOR TREATING CANCERS WITH MODIFIED PBMCsApplication 63190194Pending
- Methods For Delivering Genome Editing Molecules To The Nucleus Or Cytosol Of A Cell And Uses ThereofApplication 63186651Pending
- Methods For Treating Cancer With Enhanced Antigen Presenting CellsApplication 63369752Pending
- Microfluidic Chip Having Increased Throughput For Use In A System For Delivery Of A Payload Into A CellApplication 63131423Pending
- Formulations Of Activating Antigen CarriersApplication 63131457Pending
- Formulations Of Activating Antigen CarriersApplication PCTUS2021073142Pending
- High-throughput Microfluidic Chip Having Parallelized Constrictions For Perturbing Cell MembranesApplication 63131430Pending
- METHODS FOR TREATING CANCERS WITH MODIFIED PBMCsApplication 63131504Pending
- Methods For Treating Cancer With Activating Antigen CarriersApplication 63131506Pending
- Formulations Of PbmcsApplication 63131454Pending
- Combination Therapy With Modified Pbmcs And An ImmunoconjugateApplication 63105135Pending
- Methods To Stimulate Hla-agnostic Immune Responses To Proteins Using Nucleated CellsApplication 63147473Pending
Related companies, and why
- Stipple BioSimilar federal contract value in Biotech · null in contracts
- Nostopharma, LLCSimilar federal contract value in Biotech · null in contracts
- PROLYNX, LLCSimilar federal contract value in Biotech · null in contracts
- KSQ TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Kite Pharma, Inc.Similar federal contract value in Biotech · null in contracts
- STELLATE DNA LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .